MiMedx Group (NASDAQ:MDXG) Now Covered by Analysts at Citizens Jmp

Citizens Jmp started coverage on shares of MiMedx Group (NASDAQ:MDXG) in a research report report published on Monday, MarketBeat Ratings reports. The firm issued a market outperform rating and a $10.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the company. Mizuho lowered their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Citigroup assumed coverage on shares of MiMedx Group in a research note on Monday. They issued a “market outperform” rating for the company. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Finally, UBS Group set a $10.00 price target on shares of MiMedx Group in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $5.33 on Monday. The business has a 50-day moving average price of $5.86 and a two-hundred day moving average price of $6.62. MiMedx Group has a 1-year low of $4.89 and a 1-year high of $8.46. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. The company has a market cap of $789.37 million, a P/E ratio of 19.74 and a beta of 1.59.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. First Light Asset Management LLC grew its holdings in shares of MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after buying an additional 1,725,458 shares during the last quarter. Nantahala Capital Management LLC bought a new position in MiMedx Group in the 3rd quarter valued at about $10,237,000. Marshall Wace LLP boosted its stake in MiMedx Group by 864.9% during the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after purchasing an additional 1,238,132 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new position in shares of MiMedx Group during the fourth quarter valued at approximately $7,134,000. Finally, Disciplined Growth Investors Inc. MN lifted its stake in MiMedx Group by 283.0% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after acquiring an additional 1,022,202 shares in the last quarter. 79.15% of the stock is owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.